Hereditary angioedema: a current state-of-the-art review, II: historical perspective of non-histamine-induced angioedema
- PMID: 18220145
- DOI: 10.1016/s1081-1206(10)60579-0
Hereditary angioedema: a current state-of-the-art review, II: historical perspective of non-histamine-induced angioedema
Abstract
Objective: To review the evolution of our understanding of hereditary angioedema (HAE) from the first historical reference to the present day.
Data sources: MEDLINE and PubMed were searched using the following keywords: history of HAE, C1 inhibitor, complements system, genetics of HAE, mechanisms of HAE, and treatment of HAE.
Study selection: Information was selected that outlines the advances made in complementology, the first report of HAE, and subsequent studies that elucidated the underlying mechanisms of this disease, leading to current therapy of this orphan disease.
Results: Generational research efforts in HAE have focused on the following: (1) several new clinical presentations, (2) acquired forms of non-histamine-induced angioedema, (3) the genetic basis for the inherited forms, (4) the effects of C1 inhibitor on contact phases of coagulation-fibrinolytic pathways, and (5) various therapies for short- and long-term control of the disease.
Conclusion: The progress made in understanding the pathogenesis and treatment of HAE is an excellent example of the "bench to the bedside" paradigm involving the collaboration between clinicians and researchers.
Similar articles
-
Hereditary angiodema: a current state-of-the-art review, IV: short- and long-term treatment of hereditary angioedema: out with the old and in with the new?Ann Allergy Asthma Immunol. 2008 Jan;100(1 Suppl 2):S13-8. doi: 10.1016/s1081-1206(10)60581-9. Ann Allergy Asthma Immunol. 2008. PMID: 18220147
-
HAE update: determining optimal patient specific therapy.Allergy Asthma Proc. 2013 Jan-Feb;34(1):7-12. doi: 10.2500/aap.2013.34.3624. Allergy Asthma Proc. 2013. PMID: 23406928 Review.
-
Hereditary angiodema: a current state-of-the-art review, VI: novel therapies for hereditary angioedema.Ann Allergy Asthma Immunol. 2008 Jan;100(1 Suppl 2):S23-9. doi: 10.1016/s1081-1206(10)60583-2. Ann Allergy Asthma Immunol. 2008. PMID: 18220149 Review.
-
Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group.Allergy. 2012 Feb;67(2):147-57. doi: 10.1111/j.1398-9995.2011.02751.x. Epub 2011 Nov 30. Allergy. 2012. PMID: 22126399
-
Pathogenesis and laboratory diagnosis of hereditary angioedema.Allergy Asthma Proc. 2009 Sep-Oct;30(5):487-92. doi: 10.2500/aap.2009.30.3277. Allergy Asthma Proc. 2009. PMID: 19843402
Cited by
-
Optimal medical management of acute attacks of acquired angioedema.Mayo Clin Proc. 2010 Jan;85(1):101; author reply 101. doi: 10.4065/mcp.2009.0544. Mayo Clin Proc. 2010. PMID: 20042567 Free PMC article. No abstract available.
-
Current and emerging management options for hereditary angioedema in the US.Drugs. 2008;68(18):2561-73. doi: 10.2165/0003495-200868180-00003. Drugs. 2008. PMID: 19093699 Review.
-
Conestat alfa for the treatment of angioedema attacks.Ther Clin Risk Manag. 2011;7:265-73. doi: 10.2147/TCRM.S15544. Epub 2011 Jul 1. Ther Clin Risk Manag. 2011. PMID: 21753889 Free PMC article.
-
A hereditary angioedema screening in two villages, based on an index case, and identification of a novel mutation, "1033G>T", at the SERPING1 gene.Postepy Dermatol Alergol. 2019 Aug;36(4):403-411. doi: 10.5114/ada.2018.78898. Epub 2019 Aug 30. Postepy Dermatol Alergol. 2019. PMID: 31616213 Free PMC article.
-
2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema.Allergy Asthma Clin Immunol. 2010 Jul 28;6(1):24. doi: 10.1186/1710-1492-6-24. Allergy Asthma Clin Immunol. 2010. PMID: 20667127 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources